{"id":"tp-40645","type":"article-newspaper","title":"Summit Reports 25% Lower Death Risk in Biliary Tract Cancer Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40645","datePublished":"2026-10-25T18:41:06.000Z","dateModified":"2026-10-25T18:41:06.000Z","language":"en","abstract":"Median overall survival was 14.9 months with ivonescimab and chemotherapy, versus 12.1 months with durvalumab and chemotherapy in the late-stage trial conducted in China.","section":"Business","references":[]}